Exosomal MicroRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma.
Exosomal MicroRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma.
复制标题
外泌体 MicroRNA 特征作为胆囊癌非侵入性诊断的有效生物标志物
DOI：
10.1016/j.isci.2022.104816
复制
发表时间：
2022-09-16
期刊：
影响因子：
5.8
通讯作者：
Wang, Hongyang
中科院分区：
文献类型：
--
作者：
Yang, Pinghua;Song, Fengliang;Yang, Xinwei;Yan, Xingzhou;Huang, Xinyu;Qiu, Zhengjun;Wen, Zhijian;Liang, Chi;Xin, Xianglei;Lei, Zhengqin;Zhang, Kecheng;Yang, Jue;Liu, Hu;Wang, Hongcheng;Xiang, Shijun;Li, Liang;Zhang, Baohua;Wang, Hongyang
通过依赖于生物标志物发现、训练和验证的三步研究，我们确定了一组可用于评估胆囊癌（GBC）风险的五种外泌体microRNA（miRNA），包括miR-552- 3 p、miR-581、miR-4433 a-3 p、miR-496和miR-203 b-3 p。当在来自多个医学中心的102名GBC患者和112名慢性胆囊炎患者中验证时，该组合生物标志物的AUC为0.905，灵敏度为81.37%，特异性为86.61%。该生物标志物的性能上级标准生物标志物CA 199和CEA，适合GBC的早期诊断。GBC患者的多种临床病理特征和预后与该生物标志物显著相关。在构建了miRNA-靶基因调控网络后，研究了这5种miRNA调控的细胞功能和信号通路。该生物标志物特征可用于开发用于GBC诊断、筛查和预后预测的非侵入性工具。通过三步研究确定了五个外泌体miRNAs集以诊断GBC。这种非侵入性生物标志物的功效上级常规生物标志物。这种生物标志物与多种GBC临床特征和预后相关。估计了这种生物标志物可能影响的功能和信号通路。健康科学;癌症系统生物学;癌症
Through a three-step study that relies on biomarker discovery, training, and validation, we identified a set of five exosomal microRNAs (miRNAs) that can be used to evaluate the risk of gallbladder carcinoma (GBC), including miR-552-3p, miR-581, miR-4433a-3p, miR-496, and miR-203b-3p. When validated in 102 GBC patients and 112 chronic cholecystitis patients from multiple medical centers, the AUC of this combinatorial biomarker was 0.905, with a sensitivity of 81.37% and a specificity of 86.61%. The performance of this biomarker is superior to that of the standard biomarkers CA199 and CEA and is suited for GBC early diagnosis. The multi-clinicopathological features and prognosis of GBC patients were significantly associated with this biomarker. After building a miRNA-target gene regulation network, cell functions and signaling pathways regulated by these five miRNAs were examined. This biomarker signature can be used in the development of a noninvasive tool for GBC diagnosis, screening and prognosis prediction. A five exosomal miRNAs-set is identified to diagnose GBC through a three-step study The efficacy of this noninvasive biomarker is superior to that of conventional ones This biomarker is correlated with multiple GBC clinical features and the prognosis The functions and signal pathways that this biomarker may affect were estimated Health sciences; Cancer systems biology; Cancer
登录
查看更多内容
DOI：
10.1126/science.aau6977
发表时间：
2020-02-07
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Kalluri R;LeBleu VS
通讯作者：
LeBleu VS
影响因子：
3.7
作者：
Gallo A;Tandon M;Alevizos I;Illei GG
通讯作者：
Illei GG
影响因子：
11.5
作者：
Jin, Xiance;Chen, Yanfan;Xie, Congying
通讯作者：
Xie, Congying
影响因子：
4.6
作者：
Ueta E;Tsutsumi K;Kato H;Matsushita H;Shiraha H;Fujii M;Matsumoto K;Horiguchi S;Okada H
通讯作者：
Okada H
影响因子：
64.8
作者：
Melo SA;Luecke LB;Kahlert C;Fernandez AF;Gammon ST;Kaye J;LeBleu VS;Mittendorf EA;Weitz J;Rahbari N;Reissfelder C;Pilarsky C;Fraga MF;Piwnica-Worms D;Kalluri R
通讯作者：
Kalluri R